An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Chemomab Therapeutics, a clinical stage biotechnology company, will report its first quarter 2024 financial results and provide a business update on May 9, 2024. The company focuses on developing innovative therapeutics for fibro-inflammatory diseases. Investors can contact the company at IR@chemomab.com for further discussions.
Chemomab Therapeutics, un'azienda biotecnologica in fase clinica, riporterà i risultati finanziari del primo trimestre del 2024 e fornirà un aggiornamento aziendale il 9 maggio 2024. L'azienda si concentra sullo sviluppo di terapie innovative per le malattie fibro-infiammatorie. Gli investitori possono contattare l'azienda all'indirizzo IR@chemomab.com per ulteriori discussioni.
Chemomab Therapeutics, una empresa biotecnológica en etapa clínica, reportará sus resultados financieros del primer trimestre de 2024 y proporcionará una actualización empresarial el 9 de mayo de 2024. La compañía se enfoca en el desarrollo de terapias innovadoras para enfermedades fibroinflamatorias. Los inversores pueden contactar a la empresa en IR@chemomab.com para discusiones adicionales.
임상 단계의 생명공학 회사인 Chemomab Therapeutics는 2024년 1분기 재무 결과를 보고하고 2024년 5월 9일에 비즈니스 업데이트를 제공할 예정입니다. 이 회사는 섬유염증성 질환에 대한 혁신적인 치료법 개발에 중점을 두고 있습니다. 투자자들은 추가적인 논의를 위해 IR@chemomab.com으로 회사에 연락할 수 있습니다.
Chemomab Therapeutics, une entreprise de biotechnologie en phase clinique, rapportera ses résultats financiers pour le premier trimestre 2024 et fournira une mise à jour sur ses activités le 9 mai 2024. L'entreprise se concentre sur le développement de thérapies innovantes pour les maladies fibro-inflammatoires. Les investisseurs peuvent contacter l'entreprise à IR@chemomab.com pour des discussions supplémentaires.
Chemomab Therapeutics, ein biotechnologisches Unternehmen in der klinischen Phase, wird seine Finanzergebnisse für das erste Quartal 2024 am 9. Mai 2024 bekannt geben und ein Geschäftsupdate bereitstellen. Das Unternehmen konzentriert sich auf die Entwicklung innovativer Therapien für fibro-inflammatorische Krankheiten. Investoren können das Unternehmen unter IR@chemomab.com für weitere Diskussionen kontaktieren.
Positive
None.
Negative
None.
TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time.
Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at IR@chemomab.com.
About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information about Chemomab, visit chemomab.com.
Contacts:
Media and Investors: Barbara Lindheim Consulting Vice President, Investor & Public Relations, Strategic Communications Phone: +1 917-355-9234 barbara.lindheim@chemomab.com IR@chemomab.com
FAQ
When will Chemomab Therapeutics report its first quarter 2024 financial results?
Chemomab Therapeutics will report its first quarter 2024 financial results on May 9, 2024.
What kind of diseases does Chemomab Therapeutics focus on developing therapeutics for?
Chemomab Therapeutics focuses on developing therapeutics for fibro-inflammatory diseases.
How can investors discuss the financial results or business update with Chemomab Therapeutics?
Investors can contact the company at IR@chemomab.com for discussions on the financial results or business update.
What is the ticker symbol for Chemomab Therapeutics?
The ticker symbol for Chemomab Therapeutics is CMMB.
Chemomab Therapeutics Ltd. American Depositary Share
chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).
